Eye test may predict schizophrenia drug response, but study stalls
NCT ID NCT04986072
First seen Dec 15, 2025 · Last updated Jun 15, 2026 · Updated 24 times
Summary
This study aimed to see if a retinal (eye) biomarker could predict how well people with early schizophrenia respond to sodium nitroprusside, an anti-inflammatory drug. It planned to enroll people diagnosed within the last 5 years, but was terminated after only 1 participant. The goal was to measure changes in psychosis symptoms and cognition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.